Marie Bonnet-Di Placido1, Helen M E Duyvesteyn2, Angela W Steyn1, Abigail L Hay1, Claudine Porta2, Kristel Ramirez Valdez1, Elena Lokhman1, Sylvia Crossley1, Kevan Hanson1, William N Mwangi1, Danish Munir1, Eva Perez-Martin1, Nick J Knowles1, Alison Burman1, Abdelaziz A Yassin1, Amin Asfor1, Cristina Faralla3, Katherine J Lam3, Róisín McComb3, Carina Leifeld4, Kimberly Pietersz4, Donald P King1, Erwin van den Born4, Sherie K Duncan3, Bryan Charleston1, Elizabeth E Fry2, Jingshan Ren2, David I Stuart5,6,7, John A Hammond8
1The Pirbright Institute, Pirbright, Surrey, UK.
2Division of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK.
3AbCellera Biologics Inc, Vancouver, BC, Canada.
4MSD Animal Health, Boxmeer, AN, The Netherlands.
5Division of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK. dave.stuart@strubi.ox.ac.uk.
6Pandemic Sciences Institute, Nuffield Department of Medicine,, University of Oxford, Oxford, UK. dave.stuart@strubi.ox.ac.uk.
7CAMS Oxford Institute, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK. dave.stuart@strubi.ox.ac.uk.
8The Pirbright Institute, Pirbright, Surrey, UK. john.hammond@pirbright.ac.uk.